Karen Smith-Pilkington's Insider Trades & SAST Disclosures
Karen Smith-Pilkington's most recent trade in Carters Inc was a trade of 447 Common Stock done at an average price of $41.3 . Disclosure was reported to the exchange on Feb. 28, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Karen Smith-Pilkington.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Carters Inc | Karen Marie Smith | EVP, Supply Chain | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.27 per share. | 28 Feb 2025 | 447 | 42,557 (0%) | 0% | 41.3 | 18,448 | Common Stock |
| Carters Inc | Karen Marie Smith | EVP, Supply Chain | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 17,724 | 43,681 (0%) | 0% | 0 | Common Stock | |
| Carters Inc | Karen Marie Smith | EVP, Supply Chain | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.15 per share. | 26 Feb 2025 | 677 | 43,004 (0%) | 0% | 42.2 | 28,536 | Common Stock |
| Skye Bioscience Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Aurinia Pharmaceuticals Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 18,641 | 18,641 | - | - | Director Stock Option (right to buy) | |
| Aurinia Pharmaceuticals Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 12,135 | 24,807 (0%) | 0% | 0 | Common Shares | |
| Aurinia Pharmaceuticals Inc | Karen L. Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2024 | 17,913 | 17,913 (0%) | 0% | - | Common Stock | |
| Aurinia Pharmaceuticals Inc | Karen L. Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2024 | 17,913 | 0 | - | - | Restricted Stock Units | |
| Aurinia Pharmaceuticals Inc | Karen L. Smith | Director | Sale of securities on an exchange or to another person at price $ 8.43 per share. | 08 Nov 2024 | 5,241 | 12,672 (0%) | 0% | 8.4 | 44,182 | Common Stock |
| Skye Bioscience Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2024 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Context Therapeutics Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Sep 2024 | 19,315 | 19,315 | - | - | Stock Option (right to buy) | |
| Carters Inc | Karen Marie Smith | EVP Supply Chain | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.09 per share. | 12 Aug 2024 | 1,134 | 25,957 (0%) | 0% | 62.1 | 70,410 | Common Stock |
| Skye Bioscience Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jul 2024 | 40,000 | 40,000 | - | - | Director Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 25,000 | 77,100 (0%) | 0% | 0 | Common Stock | |
| Carters Inc | Smith Karen Marie | EVP Supply Chain | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 3,968 | 23,123 (0%) | 0% | 0 | Common Stock | |
| Carters Inc | Karen Marie Smith | EVP Supply Chain | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 3,968 | 27,091 (0%) | 0% | 0 | Common Stock | |
| Carters Inc | Karen Smith Marie | EVP Supply Chain | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.55 per share. | 27 Feb 2024 | 646 | 19,155 (0%) | 0% | 80.5 | 52,035 | Common Stock |
| Aurinia Pharmaceuticals Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2023 | 28,959 | 28,959 | - | - | Stock Option (right to buy) | |
| Aurinia Pharmaceuticals Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2023 | 17,913 | 17,913 | - | - | Restricted Stock Units | |
| Carters Inc | Karen Marie Smith | EVP Supply Chain | Payment of exercise price or tax liability using portion of securities received from the company at price $ 73.37 per share. | 12 Aug 2023 | 1,143 | 19,801 (0%) | 0% | 73.4 | 83,862 | Common Stock |
| Sangamo Therapeutics Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 27,750 | 27,750 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 13,900 | 52,100 (0%) | 0% | 0 | Common Stock | |
| Carters Inc | Karen Marie Smith | EVP Supply Chain | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2023 | 5,404 | 20,944 (0%) | 0% | 0 | Common Stock | |
| Carters Inc | Karen Marie Smith | EVP Supply Chain | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2023 | 5,404 | 15,540 (0%) | 0% | 0 | Common Stock | |
| Quince Therapeutics Inc | Karen L. Smith | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 225,000 | 225,000 | - | - | Employee Stock Option (right to buy) | |
| Carters Inc | Karen Marie Smith | EVP Supply Chain | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2022 | 10,136 | 10,136 (0%) | 0% | 0 | Common Stock | |
| Talaris Therapeutics Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 14,501 | 14,501 | - | - | Stock Option (Right to Buy) | |
| Quince Therapeutics Inc | Karen L. Smith | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 170,354 | 194,690 (0%) | 0% | 0 | Common Stock | |
| Talaris Therapeutics Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2022 | 29,002 | 29,002 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 12,500 | 38,200 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Karen L. Smith | EVP, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.85 per share. | 07 May 2021 | 305 | 11,888 (0%) | 0% | 60.8 | 18,559 | Common Stock |
| Sangamo Therapeutics Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 16,400 | 16,400 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 8,200 | 25,700 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Karen L. Smith | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 11,765 | 11,765 | - | - | Employee Stock Options (Right to Buy) | |
| Emergent Biosolutions Inc | Karen L. Smith | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 2,942 | 9,252 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Karen L. Smith | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 2,941 | 12,193 (0%) | 0% | 0 | Common Stock | |
| Sangamo Therapeutics Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2020 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2020 | 10,000 | 17,500 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges